Clinical trial

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Recruiting now · Phase 3 · 6 countries · Registry ID NCT07745504

Recruiting nowPhase 3Interventional

What this study is about

The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionOverweight, Obesity

Full registry criteria

Inclusion criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (\>=) 30.0 kilograms per square meter (kg/m\^2), or BMI \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Exclusion criteria: * History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D). * Previous dosing of marketed or non-marketed amylin-based compounds. * Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.

Treatments and study arms

Cagrilintide

Drug

Cagrilintide will be administered subcutaneously.

Placebo cagrilintide

Drug

Placebo matched to cagrilintide will be administered subcutaneously.

Placebo semaglutide

Drug

Placebo matched to semaglutide will be administered subcutaneously.

Primary outcomes

Relative change in body weightFrom baseline (week 0) to end of treatment (week 26)

Measured as percentage (%).

Study locations

36 locations were listed when this page was built. The first 40 are shown.

General Hospital Of Athens Alexandra - Department of Endocrinology, Diabetes Center🇬🇷 Athens, Greece